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Selective depletion of alloreactive T cells leads to long-term islet allograft
survival across a major histocompatibility complex mismatch in diabetic
mice
Abstract
Islet cell transplantation as a therapy for type 1 diabetes has been limited by progressive graft loss. Significant
immunosuppression including T-cell ablation has been used in an attempt to limit islet rejection. Here, we
show that CD3+ lymphocytes depleted of alloreactive T cells selected from a mixed lymphocyte reaction
(MLR), where responder BALB/c splenocytes stained with carboxyfluorescein succinimidyl ester (CFSE)
were stimulated with irradiated C57BL/6 splenocytes for 5 days, infused into diabetic immunodeficient mice
are capable of restoring a broad T-cell repertoire and specifically do not reject islet transplants from the strain
(C57BL/6) used in the original depletion. These mice demonstrate reconstitution with CD4+ and CD8+ T
cells, the capacity to reject third-party grafts (CBA), and restoration of interferon-γ (IFN-γ) responses to
third-party alloantigens. Over time, both forkhead box P3-positive (Foxp3+) T regulatory cells (Tregs) and γδ
T cells expand, suggesting a role for peripheral tolerance, in addition to the initial depletion of alloreactive T
cells, in long-term islet graft survival. Our results suggest that immune restoration with CD3+ lymphocytes
where alloreactive T cells are removed can restore cognate immunity without islet allograft loss and
recurrence of diabetes.
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Islet cell transplantation as a therapy for type 1 diabetes has been limited by progressive graft loss. Significant 
immunosuppression including T-cell ablation has been used in an attempt to limit islet rejection. Here, we show 
that CD3+ lymphocytes depleted of alloreactive T cells selected from a mixed lymphocyte reaction (MLR), 
where responder BALB/c splenocytes stained with carboxyfluorescein succinimidyl ester (CFSE) were stimu-
lated with irradiated C57BL/6 splenocytes for 5 days, infused into diabetic immunodeficient mice are capable 
of restoring a broad T-cell repertoire and specifically do not reject islet transplants from the strain (C57BL/6) 
used in the original depletion. These mice demonstrate reconstitution with CD4+ and CD8+ T cells, the capacity 
to reject third-party grafts (CBA), and restoration of interferon-g (IFN-g) responses to third-party alloantigens. 
Over time, both forkhead box P3-positive (Foxp3+) T regulatory cells (Tregs) and gd T cells expand, suggesting 
a role for peripheral tolerance, in addition to the initial depletion of alloreactive T cells, in long-term islet graft 
survival. Our results suggest that immune restoration with CD3+ lymphocytes where alloreactive T cells are 
removed can restore cognate immunity without islet allograft loss and recurrence of diabetes.
Key words: Islet cell transplantation; Long-term islet allograft survival;  
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peripheral immune repertoire with memory T cells lack-
ing alloreactivity may allow reduction of immune sup-
pression, limiting infection and cancer risk.
Alloreactive T cells make up around 1–10% of the T-cell 
pool (33). High-affinity alloreactive T cells proliferate 
rapidly in response to donor stimulation (23). To achieve 
tolerance, alloreactive T cells need to be deleted, inacti-
vated, or regulated while an environment that allows for 
the expansion of nonalloreactive T cells is promoted (16). 
In both bone marrow transplantation (BMT) and solid 
organ settings, strategies have been used in vivo and in 
vitro to specifically deplete allospecific T cells based on 
surface markers (14,32). Significant limitations involved 
in targeting activation markers CD25 and CD69 include 
nonspecificity, in which other activated cells, including T 
regulatory cells (Tregs), may be depleted. The escape of 
activated cells that have downregulated their activation 
markers may also occur. Rather than target alloreactive T 
cells through surface markers, it is possible to functionally 
InTroDuCTIon 
Islet cell transplantation is the only curative therapy 
for type 1 diabetes (8,10,27). Under current immuno-
suppressive regimens, up to 80% of recipients achieve 
insulin independence at 1 year. However, the success of 
this therapy has been limited by ongoing graft loss, with 
the success rate after 5 years falling to 10% (31). This 
loss appears in part to be immune mediated due to cel-
lular rejection despite ongoing immunosuppression (28). 
Further, immunosuppressive treatments have enhanced 
risks of malignancy and infection (2,3,30). Clinically, 
T-cell-depleting strategies are being used for islet cell 
transplantation. Anti-cluster of differentiation 54 (CD54) 
antibody has been used in solid organ transplantation and 
is part of many islet transplant protocols (4). However, 
the return of memory T cells requiring ongoing immu-
nosuppression and relative immunodeficiency following 
immune ablation increases infectious and cancer risks in 
these patients (25). Thus, the ability to reconstitute the 
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target alloreactive T cells using cell division (33). We 
have developed a novel strategy to remove alloreactive T 
cells in an ex vivo mixed lymphocyte reaction (MLR) sys-
tem using carboxyfluorescein succinimidyl ester (CFSE) 
to identify proliferating cells (9,39). Removal of allo-
stimulated CD4+ dividing cells prolongs donor allograft 
survival in major histocompatibility complex (MHC) 
mismatched skin [median survival time (MST) = 69] and 
heart transplant models in mice (MST > 100), although 
chronic fibrosis is found in long-term surviving cardiac 
allografts and skin grafts (9,39). This was associated with 
the skin grafts with persistent alloreactive T cells through 
the indirect pathway but not the direct pathway.
Immune restoration with lymphocyte infusions has 
been used predominantly in leukemia where donor lym-
phocytes are given to deliver an antitumor effect while 
limiting graft-versus-host disease, and lymphocyte infu-
sions have been used to restore immunity in a number of 
conditions (29). We evaluate full T-cell immune recon-
stitution with CD3+ T cells where the alloreactive cells 
have been removed (“pruning”) as a therapeutic strat-
egy to prevent pancreatic islet allograft rejection while 
maintaining the ability to reject third-party grafts across a 
major MHC mismatch in diabetic mice. 
MATerIALS AnD MeTHoDS
Animals
BALB/c (H-2d), C57BL/6 (H-2b), CBA (H-2k), and 
severe combined immunodeficient (SCID) (H-2d) mice 
were obtained from the Animal Resource Centre (Perth, 
Western Australia, Australia). Female mice aged 8–12 
weeks were used in all experiments. All mice were housed 
in filter-top cages in specific pathogen-free conditions, and 
animal ethics for this study was approved by the Sydney 
West Area Health Service Animal Ethics Committee.
MLR and Cell Sorting
BALB/c splenocytes stained with CFSE (BioScientific 
Pty. Ltd., Sydney, NSW, Australia) were stimulated with 
irradiated C57BL/6 splenocytes in an MLR for 5 days as 
described previously (9). At day 5, cells from the MLR were 
stained with anti-mouse CD3-phycoerythrin (PE) antibody 
(BD Pharmingen, North Ryde, NSW, Australia). The cells 
were sorted into CFSElowCD3+ T cells (dividing CD3+ T 
cells) and CFSEhighCD3+ T cells (nondividing allodepleted 
CD3+ T cells) on a FACSDiva (BD Biosciences, North 
Ryde, NSW, Australia). In the control group, unstimulated 
naive BALB/c splenocytes were stained with anti-mouse 
CD3-PE antibody, and naive CD3+ T cells were selected. 
Reconstitution and Flow Cytometric Analysis
SCID mice were injected intravenously with 5 ́  105 
sorted dividing CD3+ (DCD3), nondividing allodepleted 
CD3+ (NDACD3), or naive CD3+ T cells. Sorted and 
harvested cells from the MLR were analyzed on a FACScan 
(BD Biosciences) for purity and immune profile. Recon-
stitution of the peripheral blood (PB) and spleens of SCID 
was confirmed by flow cytometry as described previ- 
ously (9). Antibodies used included anti-mouse CD3-PE, 
CD3-peridinin chlorophyll protein (PerCP), CD4-PerCP, 
CD4-fluorescein isothiocyanate (FITC), CD8-PerCP, 
CD25-PE, CD69-PE, CD44-PE, CD45-Percp, H2Kb-PE, 
H2Kd-PE, T-cell receptor gd (TCRgd)-PE (BD Pharmingen), 
and forkhead box P3 (Foxp3)-PE (eBioscience, San Diego, 
CA, USA). 
Islet Isolation and Transplantation
Mouse pancreatic islet cells were isolated by Histopaque 
(Sigma-Aldrich Pty. Ltd., Castle Hill, NSW, Australia) 
density gradient after collagenase digestion (Roche, 
Dee Why, NSW, Australia) as described previously (35). 
SCID mice were made diabetic with a single injection of 
streptozotocin (190 mg/kg IP) (Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia) 8 days before transplanta-
tion. Blood glucose level (BGL) was measured with gly-
cemic strips and Accucheck III blood glucose monitor 
system (Roche). Only mice with BGL ³16 mmol/L were 
transplanted. Diabetic SCID mice were transplanted with 
C57BL/6 (donor) or CBA (third-party) islets under the 
left renal capsule with approximately 800 mouse islets 
per transplant. Successful islet function was defined by a 
BGL <10 mmol/L, and allograft rejection by a BGL >16 
mmol/L (35). 
The Pancreatic Islet Transplant Model 
MLR was performed prior to transplantation. On day 5 
of the MLR, cells were sorted into DCD3 and NDACD3 
T cells, and then 5 × 105 cells were adoptively transferred 
into SCID mice. SCID mice were injected with strepto-
zotocin 8 days before transplant. The diabetic SCID mice 
were transplanted with donor C57BL/6 islet allografts. 
A separate group of recipients that were infused with 
NDACD3 T cells were transplanted with third-party CBA 
islet allografts to ascertain the specificity of the response. 
Nephrectomy was performed >100 days posttransplanta-
tion to confirm islet allograft function.
Histological Examination of Islet Allografts
Kidneys containing the islet grafts were removed at 
selected time points after transplantation. Allografts were 
frozen in OCT compound (Tissue TCK, Miles Scientific, 
Elkhart, IN, USA) and stored at –80°C. Cryostat sections 
(5–7 mm) were used for a routine hematoxylin and eosin 
(H&E) and immunohistochemical staining of allografts for 
the detection of insulin secretion and for infiltration of CD3, 
CD4, and CD8 T cells. For insulin staining, the guinea pig 
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anti-insulin (Zymed, San Francisco, CA, USA) and rab-
bit anti-guinea pig immunoglobulin (Dako Corp., Noble 
Park, VIC, Australia) secondary antibodies (35) with the 
R.T.U. Vectastain universal ABC kit (Vector Laboratories, 
Inc, Burlingame, CA, USA) were used according to the 
manufacturer’s instructions. For allograft infiltration of T 
cells, primary anti-mouse CD3 (17A2) (eBioscience), anti-
mouse CD4 (L3T4) (BioLegend, San Diego, CA, USA), 
and anti-mouse CD8 (Ly-2) (BD Pharmingen) were used 
as described previously (9,38).
Interferon-g (IFN-g) Enzyme-Linked Immunospot 
(ELISPOT) Assay
ELISpotPLUS for mouse interferon-g (IFN-g) (MABTECH 
AB, Nacka Strand, Sweden) was used for detecting IFN-g 
production and performed according to the manufacturer’s 
instructions as described previously (9). Briefly, 3 ́  105 
splenocytes isolated from previously reconstituted recipi-
ent SCID mice of third-party CBA or donor C57BL/6 islet 
allografts were stimulated with 3 ́  105 C57BL/6 (donor), 
CBA (third-party), or BALB/c (self) splenocytes in 96-well 
plates pretreated with IFN-g antibody. After incubation 
for 24 h at 37°C, the cells were removed and the plates 
were washed. A second biotinylated anti-mouse IFN-g was 
added for 2 h at room temperature. Plates were washed, 
 streptavidin-ALP was added, and plates were incubated at 
room temperature for 1 h. Plates were developed with BCIP/
NBT-plus solution. Plates with spots were counted using 
the computer program AID Elispot6.0iSpot ELISPOT 
reader (AID GmbH, Strassberg, Germany).
Real-Time RT-PCR of TCR Vβ Repertoire and 
CDR3 Spectratyping of TCR Vβ Families
Real-time reverse transcription-polymerase chain reac-
tion (RT-PCR) of TCR Vb (TRBV) repertoire (22 families) 
by TaqMan Gene Expression Assay (Applied Biosystems, 
Carlsbad, CA, USA) and complementary determining 
region 3 (CDR3) spectratyping of these TRBV families 
on the ABI Prism 310 Genetic Analyzer (Applied Bio-
systems) were used to analyze the TRBV repertoire diver-
sity in T-cell subsets and to screen clonal expansion of 
T cells as described previously (9,39). TRBV repertoires 
and CDR3 spectratyping were assessed in splenocytes of 
reconstituted DCD3 and NDACD3 T-cell recipient SCID 
mice transplanted with donor C57BL/6 islet allografts.
Statistical Analysis
PRISM 4.0 software (GraphPad, San Diego, CA, 
USA) was used for statistical analysis for comparisons of 
matched groups to detect significance. The log-rank test 
was employed for comparison of survival data between 
groups. Survival is shown by MST. ANOVA comparison 
of means was used to compare the percentage of CD3+ T 
cells and proportion of different types of T cells in vivo; 
p < 0.05 was considered significant. ELISPOT data were 
compared by two-tailed Student’s t test with a Bonferroni 
correction for multiple analyses; p < 0.05 was considered 




On day 5 of the MLR, we analyzed the immune phe-
notype of cultured cells prior to sorting. The responding 
BALB/c CD3+ T cells were segregated into two popu-
lations, DCD3 and NDACD3 T cells (Fig. 1A), on day 
5 of MLR. The percentages of NDACD3, nondividing 
allodepleted CD4+ (NDACD4), and nondividing allode-
pleted CD8+ T cells were 43.6 ± 4.1%, 45.3 ± 1.0%, and 
38.3 ± 5.4% (Fig. 1A–C), respectively.
DCD3 T cells expressed higher levels of CD44 
(89.6 ± 0.3%) (Fig. 1D) and CD69 (74.6 ± 2.8%) (Fig. 1E) 
than NDACD3 T cells. The nondividing CD3+CD44+ and 
CD3+CD69+ proportions were 24.9 ± 7.9% (Fig. 1D) and 
22.7 ± 5.8% (Fig. 1E) of total NDACD3 T cells. There 
were similar percentages of gd+ T cells in both DCD3 
(1.1 ± 0.3%) and NDACD3 (1.2 ± 0.4%) T-cell populations 
(Fig. 1F). H-2Kd cells (Fig. 1G), but not stimulatory H-2Kb 
cells (data not shown), were found in either the DCD3 
or NDACD3 T-cell populations after MLR. Dividing 
CD4+ (DCD4) T cells had higher levels of the activation 
marker CD25 (82.9 ± 12.5%), compared to NDACD4 
T cells (18.4 ± 7.8%) (Fig. 1H). Interestingly, there was a 
relative decrease in CD4+Foxp3+ Tregs (2.3 ± 2.5%) in the 
NDACD4 T cells after the MLR (Fig. 1I) compared to 
naive BALB/c (15.3 ± 3.1%) (data not shown). 
Long-Term Islet Allograft Survival After Reconstitution 
With NDACD3 T Cells 
To test whether NDACD3 T cells could allow islet 
allograft survival, SCID mice reconstituted with either 
DCD3 or NDACD3 T cells were transplanted with donor 
C57BL/6 islet allografts. SCID mouse recipients (n = 7) 
of C57BL/6 islet allografts reconstituted with NDACD3 
T cells demonstrated prolonged islet allograft survival 
(MST > 100 days) compared with SCID mouse recipi-
ents (n = 5) reconstituted with DCD3 T cells that rejected 
C57BL/6 islet allografts (MST = 6 days, p < 0.05) (Fig. 2). 
Control SCID mice (n = 3) reconstituted with naive CD3+ 
T cells rejected their C57BL/6 islet allografts (MST = 32 
days p < 0.05) (Fig. 2). Further, SCID mice (n = 2) recon-
stituted with NDACD3 T cells rejected third-party CBA 
islet allografts (MST = 10.5 days, p < 0.05) (Fig. 2). This 
demonstrates that NDACD3 T cells do not reject MHC 
mismatched islet allografts while retaining the ability to 
reject third-party allografts.
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Figure 1. Flow cytometric analysis of MLR cell phenotype. Flow cytometric analysis showing the percentages of (A) low carboxyflu-
orescein succinimidyl ester cluster of differentiation 3 positive [CFSElowCD3+; dividing CD3 (DCD3)] (56.4 ± 4.2%) and CFSEhighCD3+ 
(nondividing allodepleted CD3; NDACD3) (43.6 ± 4.1%) T cells, (B) DCD4 (54.6 ± 1.0%) and NDACD4 (45.3 ± 1.0%) T cells, and 
(C) DCD8 (61.7 ± 5.4%) and NDACD8 T cells (38.3 ± 5.4%) relative to total CD3+, CD4+, or CD8+ T cells. After gating on CD3+ T 
cells, (D) the percentages of CD44+ were 89.6 ± 0.3% of DCD3 and 24.9 ± 7.9% of NDACD3 T cells, and (E) the percentages of CD69+ 
were 74.6 ± 2.8% of DCD3 and 22.7 ± 5.8% of NDACD3 T cells. (F) The percentages of T-cell receptor gd+ were 1.1 ± 0.3% in DCD3 
and 1.2 ± 0.4% in NDACD3 T cells. (G) No stimulatory H-2Kd- cells were found in both DCD3 and NDACD3 T cells. After gating on 
CD4+ T cells, (H) the percentages of CD25+ were 82.9 ± 12.5% of DCD4 and 18.4 ± 7.8% of NDACD4 T cells, and (I) the percentages 
of forkhead box P3 positive (Foxp3+) were 11.4 ± 2.0% of DCD4 and 2.3 ± 2.5% of NDACD4 T cells [data are representative of three 
separate mixed lymphocyte reaction (MLR) experiments]. 
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Histology Demonstrates Intact Islet Grafts With 
Limited Infiltrate in the NDACD3 Group 
Long-term islet allografts were evaluated for the pres-
ence of infiltrating CD3+, CD4+, and CD8+ T cells and 
insulin by immunohistochemistry (Fig. 3). Histology of 
C57BL/6 islet allografts from SCID mice reconstituted 
with DCD3 T cells demonstrated massive cellular infil-
tration (Fig. 3A, C, E, G, I) and loss of insulin staining 
(Fig. 3C). In contrast, long-term islet allografts had no 
T-cell infiltrates, and a large number of intact islets were 
found in long-term allografts, with an occasional T cells 
at the periphery of the islet allografts (Fig. 3B, D, F, H, J), 
showing strong staining for insulin (Fig. 3D). 
Successful T-Cell Reconstitution in All Groups 
To determine whether T-cell reconstitution was suc-
cessful, we examined SCID mouse peripheral blood 
(PB) and spleen by flow cytometry for the percentage 
of CD3+ T cells in the CD45+ subset. A control dot blot 
from the PB of SCID mice before reconstitution is shown 
(Fig. 4A). Representative dot blots show the CD3+CD45+ 
T cells in the PB of SCID mice reconstituted with naive 
CD3+ (6.9%), DCD3 (5.2%), and NDACD3 (7.4%) T cells 
16 days after reconstitution (Fig. 4B–D). Although there 
was a difference initially (16 days after reconstitution), 
they were similar 24 days after reconstitution in all groups 
(Fig. 4E). Further, after transplantation, there was also no 
significant difference in reconstitution between groups 
(Fig. 4F). The percentage of CD3+CD45+ increased over 
time (Fig. 4E, F). The equivalent level of reconstitution 
between groups suggests that differences in survival are 
not due to differences in reconstitution.
CD4+ and CD8+ T-Cell Subsets in All Groups of 
SCID Mouse Recipients 
To investigate whether there were differences among 
T-cell subsets of reconstitution, CD4+ and CD8+ T cells were 
assessed in the PB and spleen of SCID mouse recipients. 
Both CD4+ and CD8+ T-cell subsets were reconstituted in 
SCID mice in all groups (Table 1). There was a similar pro-
portion of the CD8+ T-cell subset in the DCD3 (4.7 ± 4.5% 
in PB and 4.9 ± 4.4% in spleen) and NDACD3 T cells 
(4.6 ± 1.6% in PB and 3.9 ± 2.0% in spleen) of SCID mouse 
recipients (Table 1). Although there was an initial decrease 
in the CD8+ T-cell subset in the DCD3 and NDACD3 
groups as compared with naive CD3+ T-cell reconstituted 
SCID mouse recipients (17.0 ± 4.7% in PB and 19.2 ± 7.1% 
in spleen) and naive BALB/c mice (21.7 ± 6.0% in PB and 
24.2 ± 8.0% in spleen), over time the proportion of CD8+ 
T cells in CD3+ T-cell reconstituted SCID mouse recipi-
ents surviving long-term was restored (12.6 ± 7.0% in PB 
and 16.8 ± 8.3% in spleen) (Table 1). The equivalent level 
of reconstitution between groups suggests that differences 
in survival are not due to differences in reconstitution of 
CD4+ and CD8+ T-cell populations.
Diversity of the T-Cell Repertoires After Reconstitution 
in Both the DCD3 and NDACD3 Groups
In order to investigate the diversity of the T-cell rep-
ertoire after reconstitution, TCR Vb (TRBV) repertoires and 
CDR3 spectratyping of TRBV families were assessed in 
both spleens of SCID mouse recipients of C57BL/6 allo-
grafts reconstituted with DCD3 T cells (DCD3-C57BL/6) 
and NDACD3 T cells (NDACD3-C57BL/6) (Fig. 5). Both 
groups were reconstituted with almost a full repertoire of 
Figure 2. Reconstitution with NDACD3 T cells led to long-term specific islet allograft survival. 
Severe combined immunodeficient (SCID) mice reconstituted with NDACD3 show long-term spe-
cific C57BL/6 islet allograft survival (white circle) [median survival time (MST) >100 days, n = 7] 
compared to DCD3-SCID mice that rejected C57BL/6 islet allografts (black triangle) (MST = 6 days, 
n = 5) (p < 0.05), naive CD3-SCID mice that rejected C57BL/6 islet allografts (white square) (MST = 32 
days, n = 3) (p < 0.05), and NDACD3-SCID mice rejected third-party CBA islet allografts (black dia-
mond) (MST = 10.5 days, n = 2) (p < 0.05) (data are from three separate experiments).
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Figure 3. Histological assessment of islet allografts by H&E staining and immunohistochemical 
staining for islet insulin content, infiltrating CD3+ T cells, CD4+ T cells, and CD8+ T cells. (A) H&E, 
(C) insulin, (E) CD3+, (G) CD4+, and (I) CD8+ are islet allografts from SCID recipient reconstituted 
with DCD3 and loss of graft function was observed 22 days posttransplantation. (B) H&E, (D) insu-
lin, (F) CD3+, (H) CD4+, and (J) CD8+ are long-term islet allografts from SCID reconstituted with 
NDACD3 on day 84 posttransplantation. (A, C, E, G, I) There was greater cellular infiltration and 
no insulin staining in rejecting C57BL/6 allografts. (B, D, F, H, J) No cellular infiltration, minimal 
T cells surrounding the edge of allografts, and a large number of intact islets present with intense 
insulin staining in long-term allografts.
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TRBV families (except TRBV23) (Fig. 5A). However, 
CDR3 spectratyping for CDR3 length of the five TRBV 
families that had greater than 5% (Fig. 5B) and the other 
16 TRBV families (less than 5%) (data not shown) of the 
repertoire showed a broad Gaussian distribution in all 
mice reconstituted with NDACD3 T cells. This suggests 
a very diverse TCR repertoire as compared to the mice 
reconstituted with DCD3 T cells that showed skewed 
CDR3 distributions and fewer peaks suggestive of a 
degree of TCR repertoire restriction and oligoclonality. 
Increased Expression of Foxp3 and the Proportion of 
gd T Cells in Mice With Long-Term Islet Transplants 
We noted two potential mechanisms for regulation 
in addition to the removal of alloreactive T cells. First, an 
expansion of Tregs over time in the long-term islet allo-
graft recipients; second, an expansion of CD3+gd+ T cells. 
In order to determine whether Tregs had a role in prolong-
ing allograft survival in SCID mice reconstituted with 
NDACD3 T cells, the populations of CD4+CD25+ and 
CD4+Foxp3+ were assessed in all groups. After MLR, there 
Figure 4. Successful T-cell reconstitution in SCID mice in all groups. Dot plot showing (A) the absence of CD3+ T cells in control 
unreconstituted SCID mice (0.5 ± 0.1%, n = 3), and the proportion of CD3+CD45+ T cells in peripheral blood (PB) of SCID reconsti-
tuted with (B) naive CD3 (CD3) (6.9%), (C) DCD3 (5.2%), and (D) NDACD3 T cells (7.4%) day 16. (E) Graph showing the percent-
age of CD3+CD45+ T cells in PB of SCID reconstituted with naive CD3+ (5.3 ± 1.9%) (p < 0.05) (n = 3), DCD3 (4.2 ± 2.6%) (p < 0.05) 
(n = 9), and NDACD3 (8.3 ± 2.1%) (n = 11) on day 16 of reconstitution, and naive CD3+ (5.3 ± 1.3%) (n = 3), DCD3 (3.5 ± 0.5%) (n = 6), 
and NDACD3 (5.8 ± 1.4%) (n = 3) on day 24 of reconstitution. (F) Percentage of CD3+CD45+ T cells in PB and spleens of receipt SCID 
mice reconstituted with naive CD3+ T cells on days 33–38 posttransplantation (13.9 ± 6.4% in PB, 26.5 ± 13.3% in spleens) (n = 3), 
DCD3 (8.4 ± 4.6% in PB, 12.4 ± 6.7% in spleens) (n = 5) and NDACD3 (10.8 ± 7.2% in PB, 22.2 ± 16.3% in spleens) (n = 4) on days 
7–26 posttransplantation, and NDACD3 on day ³84 posttransplantation (18.0 ± 13.4% in PB, 15.5 ± 6.2% in spleens) (n = 4 in PB, n = 3 
in spleen) (data are from three separate experiments).
Table 1. Proportion of CD4+ and CD8+ T Cells in Recipient SCID Mice After Transplantation













Naive BALB/c 76.9 ± 5.6 21.7 ± 6.0 71.4 ± 8.6 24.2 ± 8.0 3 —
Naive CD3 82.4 ± 4.7 17.0 ± 4.7 78.1 ± 4.2 19.2 ± 7.1 3 33–38
DCD3 92.1 ± 7.8 4.7 ± 4.5 92.7 ± 4.1 4.9 ± 4.4 4 7–22
NDACD3 95.0 ± 2.2 4.6 ± 1.6 91.4 ± 4.4 3.9 ± 2.0 4 7–26
NDACD3 87.3 ± 7.0 12.6 ± 7.0 83.2 ± 12.5 16.8 ± 8.3 3 ≥84
a Days posttransplantation (all data from three separate experiments). CD4, cluster of differentiation 4; SCID, severe 
combined immunodeficient; PB, peripheral blood; DCD3, dividing CD3+ cells; NDACD3, nondividing allodepleted 
CD3+ cells. 
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was a relative loss of CD4+Foxp3+ Tregs in both DCD4 
and NDACD4 T cells (Fig. 1I). High levels of CD25 in the 
DCD4 T cells (82.9 ± 12.5%) and also significant expres - 
sion of CD25 in the NDACD4 T cells (18.4 ± 7.8%) after 
MLR were observed, reflecting its role as an activation 
marker (Fig. 1H). The proportions of CD4+CD25+ T cells 
in PB of SCID mouse recipients of the DCD3-C57BL/6 
group at the time of rejection (5.3 ± 1.1%) and the NDACD3 
group at matching time points (4.3 ± 1.4%) (Fig. 6) were 
similar and significantly less than that seen in the MLR. 
However, in SCID mouse recipients of NDACD3-C57BL/6, 
the proportion of CD25+ T cells increased and graft sur- 
vival increased over time (11.0 ± 3.1%) (Fig. 6A). 
We further found that the expression of Foxp3+ in total 
CD4+ T cells was the highest in SCID mouse recipients 
of C57BL/6 allografts reconstituted with NDACD3 T 
cells (15.7%) (Fig. 6E) compared to those reconstituted 
with DCD3 (6.4 ± 1.0%) (Fig. 6D) or naive CD3+ T cells 
(11.3 ± 3.6%) (Fig. 6B), or in SCID mouse recipients of 
third-party CBA allografts reconstituted with NDACD3 
(NDACD3-CBA) (5.8 ± 2.0%) (Fig. 6C) at the time of 
rejection or matching survival time. Therefore, SCID 
mouse recipients reconstituted with NDACD3 had a higher 
proportion of Tregs, suggesting that selective expansion 
of Tregs had a role in the long-term acceptance of islet 
allografts.
gd T cells have been shown in a variety of models to be 
capable of regulatory functions. This subset of predomi-
nantly tissue-based T cells can have both regulatory and 
inflammatory properties (11,12,40). We found a high level 
of gd+ T cells in the PB from SCID mice with long-term islet 
allografts (Fig. 7). On day 15 posttransplantation, SCID 
mouse recipients of C57BL/6 allografts reconstituted with 
NDACD3 T cells showed a normal proportion of gd+ T cells 
in PB (1.0%) (Fig. 7E), which was similar to that found 
in naive BALB/c mice (1.2%) (Fig. 7A). Similar propor-
tions of gd+ T cells were found in the DCD3 (1.1 ± 0.3%) 
and NDACD3 T cells (1.2 ± 0.4%) after MLR (Fig. 1F). In 
Figure 5. Almost complete TRBV restoration after reconstitution in both the DCD3 and NDACD3 groups of SCID mice. (A) Real-
time RT-PCR showed T-cell receptor Vb (TRBV) repertoires in spleens of receipt SCID mice of C57BL/6 allografts reconstituted 
with DCD3 T cells at the time of rejection and NDACD3 T cells on day ³84 posttransplantation (a pool of three mice for each group). 
Twenty-one of 22 TRBV families (except TRBV23) were detected in both groups. (B) Complementary determining region 3 (CDR3) 
spectratyping of TRBV families, from highly represented families (>5%) in both spleens of DCD3-SCID mice at the time of rejection 
and NDACD3-SCID mice on day ³84 posttransplantation (3 mice each group), shows diversity in the NDACD3 group versus oligo-
clonality and skewing in the DCD3 group.
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long-term survivors posttransplant, gd+ T cells as a propor-
tion of CD3+ T cells were increased significantly in SCID 
mouse recipients of C57BL/6 allografts reconstituted with 
NDACD3 T cells (10.4 ± 3.6%) (Fig. 7F). This increase 
was significantly greater than that seen in all other groups 
at the time of rejection, including SCID mouse recipients 
of C57BL/6 allografts reconstituted with naive CD3+ T 
cells (2.6 ± 1.2%) (p < 0.05) (Fig. 7B) or dividing CD3+ 
T cells (2.1 ± 0.8%) (p < 0.05) (Fig. 7D) and SCID mouse 
recipients of third-party CBA allografts reconstituted with 
nondividing CD3+ T cells (1.9 ± 0.3%) (p < 0.05) (Fig. 7C). 
This suggests that the gd T cells may have a role in pro-
longing allograft survival in this model.
Immune Response to Donors and Third Party
IFN-g ELISPOT assay was used to determine the 
number of IFN-g T cells induced by direct alloactivation 
(Fig. 8). In SCID mouse recipients of C57BL/6 allografts 
reconstituted with NDACD3 T cells, the number of IFN-g 
spots was lower after donor stimulation compared to 
third party (Fig. 8D). In contrast, the IFN-g response in 
recipients of C57BL/6 allografts reconstituted with naive 
(Fig. 8A) or DCD3 (Fig. 8C) T cells was stronger to donor 
stimulation than third party. Interestingly, mice reconsti-
tuted with NDCD3 T cells that received third-party CBA 
allografts mounted strong responses against both CBA 
and the stimulator strain C57BL/6 (Fig. 8B).
DISCuSSIon 
We have shown that immune reconstitution with CD4+ 
T cells depleted of alloreactive CD4 T cells delayed 
skin graft rejection and allowed long-term cardiac graft 
survival, but with the development of chronic rejection 
showing significant fibrosis (9,39). Here, long-term islet 
allograft survival and treatment of diabetes were achieved 
across a major MHC mismatch in mice reconstituted 
with allodepleted CD3+ T cells in vitro with restoration 
of diverse CD4+ and CD8+ T-cell repertoires that retain 
the ability to reject third-party allografts without the need 
for additional immunosuppression. The lack of fibrosis in 
Figure 6. Islet allograft survival is associated with increased expression of Foxp3. (A) The proportion of CD4+CD25+ T cells in PB 
and spleens of recipient SCID mice of C57BL/6 allografts reconstituted with DCD3 (5.3 ± 1.1% in PB, 12.2 ± 1.6% in spleen) (n = 4) 
(at the time of rejection) and NDACD3 (4.3 ± 1.4% in PB, 21.3 ± 9.8% in spleen) (n = 2) (the match time point) on days 7–26 post-
transplantation, and NDACD3T cells on day ³84 posttransplantation (11.0 ± 3.1% in PB, 18.2 ± 8.4% in spleen) (n = 3). The proportion 
of CD4+CD25+ T cells was increased in the PB of the NDACD3-C57BL/6 group (³84 days) compared to the DCD3-C57BL/6 and 
NDACD3-C57BL/6 groups (7–26 days). (B) The proportion of CD4+Foxp3+ Tregs was highest in the spleen of the (E) NDACD3-
C57BL/6 group on day 26 posttransplantation (15.7%) compared to the (B) CD3-C57BL/6 (11.3 ± 3.6%) (n = 3), (D) DCD3-C57BL/6 
(6.4 ± 1.0%) (n = 3) (at matched time points), and (C) NDACD3-CBA groups (5.8 ± 2.0%) (n = 2) at the time of rejection.
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islets as compared to that found in skin and heart mod-
els suggests that there may be additional pathways of 
immune regulation in this model potentially related to the 
broader set of T cells used for reconstitution.
As compared to vascularized grafts, islet grafts showed 
long-term survival without evidence of chronic rejection 
even under the more stringent barrier of MHC mismatched 
CD3+ T-cell reconstitution containing both CD4+ and CD8+ 
subsets. The better outcomes for islets than previously 
found in heart or skin transplants following “pruning” has 
a number of possible explanations. The islets themselves 
express predominantly class I antigens as compared to vas-
cularized or skin grafts where class II antigens are highly 
expressed on endothelium (1,26,36). However, both CD4+ 
and CD8+ T cells have been shown to be capable of reject-
ing islet allografts, making this a less likely explanation. 
It appears that in islet allograft rejection, CD4+ and CD8+ 
T cells work together, with CD4+ cells providing help for 
CD8+ cells through either the direct or indirect pathway 
(21). In NOD mice, CD4+ T cells alone can mediate rejec-
tion (21). Histologically, we find both CD4+ and CD8+ 
T cells in rejecting allografts in mice receiving DCD3 T 
cells, suggesting a role for both in rejection, whereas in 
mice that have received NDACD3 T cells, there is no cell 
infiltrate and a minimal amount of CD3+ T cells around the 
allografts. 
An additional explanation for long-term allograft sur-
vival is inadequate reconstitution or function of the adop- 
tively transferred lymphocytes. However, mice reconsti- 
tuted with either dividing or nondividing subsets demon-
strated homeostatic proliferation with CFSE dye dilution 
over time (data not shown) and reconstitution of both 
CD4+ and CD8+ subsets. The functionality of these cells was 
demonstrated by their capacity to reject third-party grafts and 
also to generate IFN-g as part of the rejection response as 
shown by ELISPOT. Therefore, even with the added func-
tionality caused by homeostatic proliferation, nondividing 
T cells did not reject grafts from the stimulator strain while 
retaining the capacity to reject third-party grafts (9).
The development of immune regulation, which was not 
found in the skin and cardiac models, might also explain 
the long-term tolerance to the islet allografts. We have 
previously noted differences in tolerance in equivalent 
MHC mismatches between kidney (tolerant) and heart 
(rejected) in the C57BL/6 to B10.BR model (37). We 
noted two potential mechanisms for regulation in addi-
tion to the removal of alloreactive T cells. This may be 
explained by the broader (CD3+) T-cell repertoire in this 
study as compared to (CD4+) in the skin and heart stud-
ies. The first is the expansion of Tregs over time in the 
long-term islet allograft recipients; this is a mechanism 
well described for maintenance of tolerance and may 
explain the lack of chronic rejection (34). Foxp3+ Tregs 
can transfer tolerance to mouse islet allografts between 
recipients (6,7,24). Elevated Foxp3 has been shown in 
tolerant liver allografts (19) and cardiac allografts (17) in 
different animal models. Foxp3 staining showed Foxp3+ 
cells in the rejecting grafts and occasional cells at the 
Figure 7. Islet allograft survival is associated with a high proportion of gd T cells. Flow cytometric analysis of gd+ T cells showed (A) the 
proportion of gd+CD3+ T cells was 1.4% in PB in naive BALB/c mice. gd T cells were significantly increased in PB of (F) NDACD3-C57BL/6 
recipient SCID mice on day ³84 posttransplantation (10.4 ± 0.6%) (n = 3) compared to the (B) CD3-C57BL/6 group (2.6 ± 1.2%) (n = 3) 
(p < 0.05), (C) NDACD3-CBA third-party group (1.9 ± 0.3%) (n = 2) (p < 0.05), and (D) DCD3-C57BL/6 group (2.1 ± 0.8%) (n = 4) (p < 0.05) 
at the time of rejection (days 7–22 posttransplantation) and to the (E) NDACD3-C57BL/6 group on day 15 posttransplantation (1.0%).
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edge of long-term tolerant grafts (data not shown). This is 
consistent with the data from thymidine kinase depletion 
in islet cell transplantation where Treg expansion is also 
found (5). Our finding that there is increased expression of 
Foxp3+ Tregs in SCID mice reconstituted with NDACD3 
T cells with donor allografts compared with other groups 
in vivo and NDACD3 after MLR suggests that induced 
Tregs or expanded naturally occurring Tregs may play a 
role in islet allograft survival in the model.
The second is the expansion of CD3+gd+ T cells. This 
subset of predominantly tissue-based T cells can have 
both regulatory and inflammatory properties (11,12,40). 
Intraepithelial gd+ T cells were required for tolerance induc-
tion using oral insulin to prevent diabetes in the nonobese 
diabetic (NOD) mouse (20). In human studies of allograft 
tolerance, increased numbers of gd+ T cells are found in 
the peripheral circulation of both adult and pediatric 
liver allograft recipients (15,22). We have also identified 
regulatory subsets of gd+ T cells in models of nephritis (40). 
Similarly, in this islet transplant model, these cells may 
potentially play a role in islet tolerance. Currently, there are 
a number of immune ablative strategies and cell therapy 
strategies, including mixed chimerism and facilitator cells, 
to achieve human tolerance. The removal of alloreactive T 
cells by pruning may assist these strategies in human cell 
and organ transplantation (13,18).
In conclusion, immune reconstitution with CD3+ lym-
phocytes depleted of alloreactive T cells promoted long-
term allograft survival without rejection despite restoration 
of CD4+ and CD8+ T cells and a broad T-cell repertoire 
associated with expansion of gd+ T cells and Foxp3+ Tregs. 
This may potentially allow profound lymphocyte depletion 
at the time of islet cell transplantation followed by recon-
stitution of the T-cell repertoire with T cells that have been 
“pruned” to allow restoration of normal immune function 
without the need for strong immunosuppression. 
Figure 8. Reduced IFN-g production in the NDACD3 group. ELISPOT assay for interferon (IFN)-g production by splenocytes from CD3-
C57BL/6, DCD3-C57BL/6, and NDACD3-CBA recipient mice at the time of allograft rejection and recipient mice with functional C57BL/6 
allografts reconstituted with NDACD3 T cells on day >100. In all four groups, there were significant differences in IFN-g production between 
cells stimulated by allogeneic C57BL/6 and syngeneic BALB/c (*p < 0.05, **p < 0.001) and between allogeneic third-party CBA (3rd) and 
BALB/c (*p < 0.05). (A) Increasing IFN-g production was found in response to the stimulator C57BL/6 strain compared with the third-party 
CBA strain in responder cells from both recipient SCID mice of C57BL/6 allografts reconstituted with naive CD3+ (195 ± 30.5 vs. 131 ± 22.6 
spots per 3 ́  105 cells) and (C) DCD3 T cells (138 ± 11.5 vs. 99 ± 21.9 spots per 3 ́  105 cells). (B) There was a similar amount of IFN-g produc-
tion when stimulated by either allogeneic stimulator C57BL/6 (285.0 ± 43.1 spots per 3 ́  105 cells) or CBA (303 ± 4.9 spots per 3 ́  105 cells) 
strain in the third-party NDACD3-CBA group. (D) There was reduced IFN-g production in response to the stimulator C57BL/6 strain (48 ± 5.6 
spots per 3 ́  105 cells) compared with the third-party CBA strain (69 ± 12.0 spots per 3 ́  105 cells) in the NDACD3-C57BL/6 group.
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